Search
-
Hybrid work (and commuting) really seem here to stay
The number of employees who say their employers have set hybrid work guidelines has increased 9 percentage points in the last year, according to new data from the Ipsos Consumer Tracker.
-
A question of gender
Read more about the importance of asking about gender in an inclusive way, especially when conducting international research.
-
February 2024: Consumer confidence down among G7 countries
Sentiment largely up in the Asia-Pacific, while it is mixed throughout Europe.
-
It's a major global election year, and populism is on the ballot
Below are five charts on where the world stands on populism and where things could head in 2024
-
ESG: A hidden driver for brand success in healthcare
Read how life sciences companies can go beyond the organizational level and apply their ESG strategy to individual brands, and how doing so with authenticity can serve as an additional factor driving brand success.
-
Half of Americans say they have been in a 10+ year age-gap relationship
New Ipsos poll finds that about seven in ten Americans rate sexual satisfaction and fun aspects higher in those relationships who have 10+ years of age difference
-
[WEBINAR] Loving or Loathing: Understanding Affluents’ Relationship with Luxury
With studies running in 50 markets around the world, we are able to offer an unparalleled understanding of how Affluents think and act – insights critical for all marketers hoping to increase share of wallet among the wealthiest consumers.
-
ASCO Annual Meeting 2024
Are you planning to be at ASCO 2024? Don’t mistake conference buzz for oncologist engagement!
-
[WEBINAR] The Inside Track: 2024 Election Briefing
Join the Ipsos polling team for our regular briefing on the data and trends transforming the country.
-
Understanding Patients with Metastatic Breast Cancer – A Preference for Oral Treatments
Research conducted by Ipsos in collaboration with Living Beyond Breast Cancer and funded by Eli Lilly and Company explores the time commitment and treatment preferences among women living with ER+, HER2- metastatic breast cancer